Valuation: BriaCell Therapeutics Corp.

Market Cap 3.23Cr 2.84Cr 2.62Cr 2.42Cr 4.58Cr 309.52Cr 4.68Cr 31Cr 12Cr 151.47Cr 12Cr 12Cr 525.81Cr P/E 2024
-2.56x
P/E 2025 -0.12x
Enterprise Value 1.45Cr 1.27Cr 1.17Cr 1.08Cr 2.05Cr 138.45Cr 2.09Cr 14Cr 5.47Cr 68Cr 5.43Cr 5.31Cr 235.2Cr EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
99.49%
Yield 2024 *
-
Yield 2025 -
1 day+6.02%
1 week+6.63%
Current month+14.20%
1 month+19.74%
3 months-16.48%
6 months-49.18%
Current year-47.96%
1 week 3.35
Extreme 3.35
3.82
1 month 2.6
Extreme 2.6
3.82
Current year 2.6
Extreme 2.6
12.1
1 year 2.6
Extreme 2.6
21.8
3 years 2.6
Extreme 2.6
1,138.5
5 years 2.6
Extreme 2.6
1,870.5
10 years 2.6
Extreme 2.6
8,424.08
Manager TitleAgeSince
Chief Executive Officer 70 01/11/2016
Director of Finance/CFO 54 01/02/2016
Chief Tech/Sci/R&D Officer 56 01/05/2021
Director TitleAgeSince
Director/Board Member 63 10/05/2016
Director/Board Member 74 07/03/2019
Director/Board Member 68 18/03/2019
Change 5-day change 1-year change 3-year change Capi.($)
+6.02%+6.63% - - 3.02Cr
-1.53%+0.78%+72.33%+129.70% 5.77TCr
-2.45%-7.83%+63.92%+83.15% 5.27TCr
+3.27%+8.91%+21.21%+486.76% 2.45TCr
-0.81%-0.42%-16.24%-12.47% 2.38TCr
-3.05%+3.06%+38.75%-5.66% 1.93TCr
-0.24%+5.11%+38.76%-26.41% 1.78TCr
+2.34%+12.50%+224.02%+380.99% 1.73TCr
-6.73%+9.90%+39.77% - 1.53TCr
-1.70%+3.98%+28.96%+190.57% 1.43TCr
Average -0.49%+5.51%+56.83%+153.33% 2.7TCr
Weighted average by Cap. -1.26%+3.12%+57.71%+141.66%

Financials

2024 2025
Net sales - -
Net income -47.91L -42.03L -38.8L -35.85L -67.96L -46Cr -69.32L -4.66Cr -1.81Cr -22Cr -1.8Cr -1.76Cr -78Cr -2.63Cr -2.31Cr -2.13Cr -1.97Cr -3.73Cr -251.94Cr -3.81Cr -26Cr -9.95Cr -123.29Cr -9.88Cr -9.66Cr -427.99Cr
Net Debt -9L -8L -7L -6L -12.23L -8.25Cr -12.47L -83.92L -32.61L -4.04Cr -32.37L -31.66L -14Cr -1.79Cr -1.57Cr -1.45Cr -1.34Cr -2.53Cr -171.07Cr -2.58Cr -17Cr -6.76Cr -84Cr -6.71Cr -6.56Cr -290.61Cr
Logo BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells. The Company is advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer. It is also developing personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+, which provides a platform technology to develop personalized off-the-shelf immunotherapies for numerous types of cancer, and a soluble CD80 protein therapeutic which act both as a stimulator of the immune system, as well as an immune checkpoint inhibitor. Its pipeline also includes Bria-IMT + CPI, Bria-BRES/BRES+, Bria-PROS+, Bria-LUNG+ and Bria-MEL+.
Employees
16
Date Price Change Volume
08/26/08 $3.700 +6.02% 3,39,625
07/26/07 $3.490 -0.29% 3,30,938
06/26/06 $3.500 +7.36% 3,59,152
02/26/02 $3.260 -6.05% 2,17,589
01/26/01 $3.470 +7.10% 1,76,651

Quarterly revenue - Rate of surprise